Outcomes4Me

Oncology Clinical Trial Finder

Breast Cancer
Location

Recruiting • Phases I, II • Stages III, IV • Medical Oncology • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

Breast Cancer

Study Design

Study type:

Interventional

Estimated enrollment:

320 participants

Actual study start date:

October 9, 2019

Eligibility Criteria

Ages eligible for study:

18 - 999

Sexes eligible for study:

both


Arms and Intervention

  • CYT-0851

  • CYT-0851 in combination with gemcitabine

  • CYT-0851 in combination with capecitabine

  • CYT-0851 in combination with rituximab and bendamustine

Trial Information at Site

Last Updated:

Trial Information

ClinicalTrial.gov ID:

Recruiting

Estimated Enrollment:

320

Last Updated:

08/29/2022


Site Contact

Dejan Juric, MD

djuric@partners.org

617-724-4000

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114


Trial Contacts

Judson Englert, MD

clinicaltrials@cyteir.com

857-285-4140


Susan Doleman

clinicaloperations@cyteir.com

857-285-4140


Principal Investigator

Judson Englert, MD


Trial Sponsor

Cyteir Therapeutics, Inc.

Study Locations (21)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Outcomes4Me

© 2023 Outcomes4Me Inc. All rights reserved.